Dose Adjustment Guidelines for Asiminib/Asnib

Asciminib/Asciminib is a first-line or late-line treatment option for chronic myelogenous leukemia (CML)CML). Adverse reaction management is extremely important during use. Reasonable dose adjustment can improve treatment tolerance and efficacy. For different patient subgroups, dose adjustment programs are targeted.

For patients with Ph-positive chronic phase CML who have previously received two or more tyrosine kinase inhibitors (TKI), the usual initial dose is 40 mg twice daily. If the patient experiences intolerable side effects, the doctor may reduce the dose to 40 mg once daily or 20 mg twice daily. If this reduction is still not tolerated, it is recommended to permanently discontinue aceminib to avoid the occurrence of serious adverse events.

For Ph-positive chronic phase CML patients carryingT315I mutation, the recommended starting dose is higher, 160 mg twice daily. Because this mutation is resistant to other TKIs, high doses of aceminib are used to ensure adequate efficacy. If the patient cannot tolerate the dose due to side effects, doctors should consider stopping the medication, looking for other treatment options or moving to clinical trials.

During medication, dosage adjustments should be dynamically adjusted based on the patient's clinical response and adverse event manifestations. Common adverse reactions include hematological toxicity, liver function abnormalities, gastrointestinal discomfort, etc., which can be treated by temporarily discontinuing the drug, reducing the dose, or supporting treatment. It is recommended that patients maintain close communication with their doctors during the medication period and conduct regular blood routine and liver and kidney function tests.

In short, the dosage adjustment of aximinin emphasizes individualized management to ensure the maximum efficacy of the drug while reducing the risk of adverse reactions and improving patients' quality of life and treatment compliance.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib